Posted in | News | Materials Analysis

Spectris plc Announces the Acquisition of La Corporation Scientifique Claisse Inc.

Spectris plc (‘Spectris’ or the ‘Company’) (LSE: SXS), the productivity-enhancing instrumentation and controls company, today announces that it has acquired the business and assets of the Canadian company La Corporation Scientifique Claisse Inc. (‘Claisse’), a global market leader in sample preparation for atomic spectroscopy (including X-ray) analysis, for an undisclosed sum. Revenues for the year ending March 2014 were CAD 13 million.

Acquisition of Corporate Scientific Claisse Inc.

Claisse designs, manufactures and sells consumables and instruments used to prepare consistent and comparable samples for spectroscopic analysis in mining, pharmaceutical, academic research and industrial applications. Claisse will become part of the Materials Analysis segment and will be integrated into PANalytical, combining two leaders in fusion and X-ray fluorescence (XRF) analysis.

Eoghan O’Lionaird, Spectris Business Group Director, said: “Claisse is a strong strategic addition to Spectris’ Materials Analysis segment as it deepens our presence within the sample preparation market.  Claisse is renowned for its innovation and fusion technology leadership, and we are confident that the market will benefit from PANalytical’s support of Claisse’s continued product and application development plans. We believe there is a strong cultural fit with PANalytical, and that the combined capabilities will create significant value for our XRF customers, as well as increasing PANalytical’s resilient revenues.”

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.